3- (4- dimethylaminobenzylidene)- 1,3- dihydroindol- 2- one

08/16/2022 - "Moreover, SU4312 decreased the M2tumor-associated macrophages and enhanced anti-tumor immunity by down-regulating the YAP-CCL2 axis. "
03/01/2013 - "The anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS."
11/01/2017 - "We have previously demonstrated the unexpected neuroprotection of the anti-cancer agent SU4312 in cellular models associated with Parkinson's disease (PD). "
08/16/2022 - "SU4312, initially designed as a multi-target tyrosine kinase inhibitor, is consequently reported to inhibit tumor angiogenesis by blocking VEGFR. "
03/01/2013 - "SU4312, a potent and selective inhibitor of VEGF receptor-2 (VEGFR-2), has been designed to treat cancer. "

03/01/2013 - "Because SU4312 could reach the brain in rats, our study also offered a support for further development of SU4312 to treat neurodegenerative disorders, particularly those associated with NO-mediated neurotoxicity."
03/01/2013 - "Recent studies have suggested that SU4312 can also be useful in treating neurodegenerative disorders. "

08/16/2022 - "In conclusion, our results suggest that SU4312 represses glioma progression by down-regulating YAP transcription and consequently CCL2 secretion. "
08/16/2022 - "The exogenous over-expression of YAP partially restored the inhibitory effect of SU4312 on glioma progression. "
08/16/2022 - "However, although SU4312 can penetrate the brain-blood barrier, its potential to inhibit glioma growth is unknown. "
08/16/2022 - "In this study, we report that SU4312 inhibited glioma cell proliferation and down-regulated yes-associated protein (YAP), the key effector of the hippo pathway. "
08/16/2022 - "SU4312 may be synergistic with temozolomide for glioma treatment."

07/01/2010 - "Incubation of cultured ganglion cells or retinal cultures containing photoreceptors with high doses of SU4312 did not reduce cell viability. "

11/01/2017 - "SU4312 thus may be an effective drug candidate for the prevention or even modification of the pathological processes of PD."